GGrantIndex
← Leaderboards

John L. Cleveland

H. Lee Moffitt Cancer Ctr & Res Inst

Google Scholar ↗PubMed ↗ORCID ↗
$27,832,236
Attributed
$33,178,614
Total exposure
22
Grants
20
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $7.2M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$62,154,308 · 23

By mechanism

P30$33,715,503 · 8
R01$26,256,408 · 10
P01$1,688,597 · 2
R21$478,800 · 2
R13$15,000 · 1

Top collaborators

Most similar at H. Lee Moffitt Cancer Ctr & Res Inst

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsProgramsCollaborationsCancer CenterFundingCatchment AreaFosteringEvaluationCancer Center Support GrantFacultyStrategic PlanningClinical TrialsLeadershipMemberResource SharingScienceGrowthDesignMalignant Neoplasm Of LungMetabolismInfrastructureInnovationMissionRecruit

Grant awards (130)

Moffitt Cancer Center Support Grant$4,054,822
P30 · FY2025 · CA · contact PI
Project 3$338,116
P01 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$302,039
P30 · FY2025 · CA · contact PI
Developmental Funds$290,536
P30 · FY2025 · CA · contact PI
Moffitt Cancer Center Support Grant$4,054,822
P30 · FY2024 · CA · contact PI
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma$526,993
R01 · FY2024 · CA · contact PI
Project 3$327,704
P01 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$302,041
P30 · FY2024 · CA · contact PI
Developmental Funds$290,538
P30 · FY2024 · CA · contact PI
Multimodal Federated Learning for Pan-Cancer Detection of Cachexia and Early Detection of Pancreatic Cancer$202,200
P30 · FY2024 · CA · contact PI
Moffitt Cancer Center Support Grant$137,979
P30 · FY2024 · CA · contact PI
Moffitt Cancer Center Support Grant$122,875
P30 · FY2024 · CA · contact PI
Moffitt Cancer Center Support Grant$4,054,822
P30 · FY2023 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$714,894
R01 · FY2023 · CA
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma$543,634
R01 · FY2023 · CA · contact PI
Project 3$338,052
P01 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$302,040
P30 · FY2023 · CA · contact PI
Applying Large Language Models to Accelerate Abstraction of Cancer Pathology Reports for Cancer Registry (LLMs for Unstructured Data Extraction)$299,999
P30 · FY2023 · CA · contact PI
Developmental Funds$290,537
P30 · FY2023 · CA · contact PI
Harnessing EHR to develop a Florida-based Coalition on Cancer Care Inequities among PHIV (Social Determinants of Health and Quality of Cancer Care in HIV-associated Cancers)$249,906
P30 · FY2023 · CA · contact PI
Moffitt Cancer Center Support Grant$236,988
P30 · FY2023 · CA · contact PI
Moffitt Cancer Center Support Grant$169,651
P30 · FY2023 · CA · contact PI
Moffitt Cancer Center Support Grant$4,054,833
P30 · FY2022 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$714,896
R01 · FY2022 · CA
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma$543,634
R01 · FY2022 · CA · contact PI
Project 3$339,774
P01 · FY2022 · CA · contact PI
Moffitt Cancer Center Support Grant$250,000
P30 · FY2022 · CA · contact PI
Developmental Funds$162,193
P30 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$162,193
P30 · FY2022 · CA · contact PI
Assessing the Efficacy of Sexual Orientation and Gender Identity (SOGI) Data Collection.$149,999
P30 · FY2022 · CA · contact PI
Moffitt Cancer Center Support Grant$115,000
P30 · FY2022 · CA · contact PI
The role of Accelerated Biological Aging in HIV control and Non-AIDS-defining Cancer Risk (Biospecimens/Biocohort)$104,167
P30 · FY2022 · CA · contact PI
Moffitt Cancer Center Support GrantDeterminants of Cancer Survivorship Among People Living with HIV (HIV/AIDS/Aging Cancer)$100,561
P30 · FY2022 · CA · contact PI
Moffitt Cancer Center Support Grant$57,009
P30 · FY2022 · CA · contact PI
Moffitt Cancer Center Support Grant$18,513
P30 · FY2022 · CA · contact PI
Moffitt Cancer Center Support Grant$2,990,966
P30 · FY2021 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$729,483
R01 · FY2021 · CA
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma$554,729
R01 · FY2021 · CA · contact PI
Administrative Core$473,066
P30 · FY2021 · CA · contact PI
Project 3$344,951
P01 · FY2021 · CA · contact PI
Developmental Funds$342,312
P30 · FY2021 · CA · contact PI
Moffitt Cancer Center Support Grant$250,000
P30 · FY2021 · CA · contact PI
Moffitt Cancer Center Support Grant$127,964
P30 · FY2021 · CA · contact PI
Planning and Evaluation$69,126
P30 · FY2021 · CA · contact PI
Moffitt Cancer Center Support Grant$64,810
P30 · FY2021 · CA · contact PI
Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement$60,000
P30 · FY2021 · CA · contact PI
Moffitt Cancer Center Support Grant$57,500
P30 · FY2021 · CA · contact PI
P30 Administrative Supplement to Cancer Center Support Grant to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network.$22,569
P30 · FY2021 · CA · contact PI
Moffitt Cancer Center Support Grant$2,990,966
P30 · FY2020 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$729,484
R01 · FY2020 · CA
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma$554,729
R01 · FY2020 · CA
Administrative Core$473,062
P30 · FY2020 · CA · contact PI
Developmental Funds$342,308
P30 · FY2020 · CA · contact PI
Epigenetic Regulation of Drug Resistance to ABT-199 in B-cell Malignancies$187,050
R21 · FY2020 · CA · contact PI
Moffitt Cancer Center Support Grant$149,981
P30 · FY2020 · CA · contact PI
Moffitt Cancer Center Support Grant$125,000
P30 · FY2020 · CA · contact PI
Moffitt Cancer Center Support Grant$115,000
P30 · FY2020 · CA · contact PI
Moffitt Cancer Center Support Grant$103,446
P30 · FY2020 · CA · contact PI
Moffitt Cancer Center Support Grant$99,999
P30 · FY2020 · CA · contact PI
Planning and Evaluation$69,122
P30 · FY2020 · CA · contact PI
Planning and Evaluation$4,498
P30 · FY2020 · CA · contact PI
Administrative Core$4,498
P30 · FY2020 · CA · contact PI
Developmental Funds$4,498
P30 · FY2020 · CA · contact PI
Moffitt Cancer Center Support Grant$2,891,925
P30 · FY2019 · CA · contact PI
Administrative Core$457,396
P30 · FY2019 · CA · contact PI
Developmental Funds$330,973
P30 · FY2019 · CA · contact PI
Moffitt Cancer Center Support Grant$248,922
P30 · FY2019 · CA · contact PI
Moffitt Cancer Center Support Grant$125,000
P30 · FY2019 · CA · contact PI
Planning and Evaluation$66,833
P30 · FY2019 · CA · contact PI
Moffitt Cancer Center Support Grant$60,000
P30 · FY2019 · CA · contact PI
Moffitt Cancer Center Support Grant$57,500
P30 · FY2019 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$678,459
R01 · FY2018 · CA
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$106,378
R01 · FY2018 · CA
High Throughput Screening to Discover Ulk1 Kinase Inhibitors$453,082
R01 · FY2017 · GM
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics$598,617
R01 · FY2016 · CA · contact PI
High Throughput Screening to Discover Ulk1 Kinase Inhibitors$453,082
R01 · FY2016 · GM
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis$349,638
R01 · FY2016 · CA · contact PI
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics$630,698
R01 · FY2015 · CA · contact PI
High Throughput Screening to Discover Ulk1 Kinase Inhibitors$621,865
R01 · FY2015 · GM
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis$349,638
R01 · FY2015 · CA · contact PI
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics$747,603
R01 · FY2014 · CA · contact PI
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis$383,525
R01 · FY2014 · CA · contact PI
The Anatomy and Regulation of Mouse Recombination Hotspots.$352,836
R01 · FY2014 · GM · contact PI
High-throughput assay development for molecular probes targeting the ULK1 kinase$340,000
R01 · FY2014 · CA · contact PI
High-throughput assay development for molecular probes targeting the ULK1 kinase$139,293
R01 · FY2014 · CA · contact PI
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis$13,374
R01 · FY2014 · CA · contact PI
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics$744,805
R01 · FY2013 · CA · contact PI
High-throughput assay development for molecular probes targeting the ULK1 kinase$464,470
R01 · FY2013 · CA · contact PI
Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer$392,303
R01 · FY2013 · CA · contact PI
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis$386,199
R01 · FY2013 · CA · contact PI
The Anatomy and Regulation of Mouse Recombination Hotspots.$340,487
R01 · FY2013 · GM · contact PI
2013 Polyamines Gordon Research Conference and Gordon Research Seminar$15,000
R13 · FY2013 · CA · contact PI
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics$793,843
R01 · FY2012 · CA · contact PI
High-throughput assay development for molecular probes targeting the ULK1 kinase$477,075
R01 · FY2012 · CA · contact PI
Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer$417,344
R01 · FY2012 · CA · contact PI
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis$410,850
R01 · FY2012 · CA · contact PI
Interplay of Myc, Tumor Supressors and Regulators of Differentiation in Lymphoma$363,164
R01 · FY2012 · CA · contact PI
The Anatomy and Regulation of Mouse Recombination Hotspots.$352,836
R01 · FY2012 · GM · contact PI
Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer$417,344
R01 · FY2011 · CA · contact PI
Interplay of Myc, Tumor Supressors and Regulators of Differentiation in Lymphoma$363,164
R01 · FY2011 · CA · contact PI
The Anatomy and Regulation of Mouse Recombination Hotspots.$352,836
R01 · FY2011 · GM · contact PI
Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer$422,647
R01 · FY2010 · CA · contact PI
Interplay of Myc, Tumor Supressors and Regulators of Differentiation in Lymphoma$367,778
R01 · FY2010 · CA · contact PI
Rapid genome-wide mapping of mammalian meiotic recombination hotspots.$291,750
R21 · FY2010 · HD · contact PI
Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer$422,647
R01 · FY2009 · CA · contact PI
Interplay of Myc, Tumor Supressors and Regulators of Differentiation in Lymphoma$367,778
R01 · FY2009 · CA · contact PI
Myc Role in Hematopoiesis, Vasculogenesis & Agiogenesis$345,824
R01 · FY2009 · DK · contact PI
Myc Role in Hematopoiesis, Vasculogenesis & Agiogenesis$345,824
R01 · FY2008 · DK · contact PI
Regulation and Role of ODC in Apoptosis and Cancer$365,189
R01 · FY2007 · CA · contact PI
Myc Role in Hematopoiesis, Vasculogenesis & Agiogenesis$352,882
R01 · FY2007 · DK · contact PI
The Bcl-2/Bcl-X Pathway in Myc-Induced Lymphomagenesis$254,225
R01 · FY2007 · CA · contact PI
The Bcl-2/Bcl-X Pathway in Myc-Induced Lymphomagenesis$275,373
R01 · FY2006 · CA · contact PI
Myc Role in Hematopoiesis, Vasculogenesis & Agiogenesis$188,241
R01 · FY2006 · DK · contact PI
Regulation and Role of ODC in Apoptosis and Cancer$178,428
R01 · FY2006 · CA · contact PI
Regulation and Role of ODC in Apoptosis and Cancer$170,190
R01 · FY2006 · CA · contact PI
Myc Role in Hematopoiesis, Vasculogenesis & Agiogenesis$146,190
R01 · FY2006 · DK · contact PI
Regulation and Role of ODC in Apoptosis and Cancer$333,750
R01 · FY2005 · CA
Myc Role in Hematopoiesis, Vasculogenesis &Agiogenesis$322,500
R01 · FY2005 · DK
The Bcl-2/Bcl-X Pathway in Myc-Induced Lymphomagenesis$282,000
R01 · FY2005 · CA
Regulation and Role of ODC in Apoptosis and Cancer$333,750
R01 · FY2004 · CA
C-MYC FUNCTION IN APOPTOSIS, HEMATOPOIESIS AND LEUKEMIA$286,875
R01 · FY2004 · DK
The Bcl-2/Bcl-X Pathway in Myc-Induced Lymphomagenesis$282,000
R01 · FY2004 · CA
Regulation and Role of ODC in Apoptosis and Cancer$331,183
R01 · FY2003 · CA
C-MYC FUNCTION IN APOPTOSIS, HEMATOPOIESIS AND LEUKEMIA$286,875
R01 · FY2003 · DK
The Bcl-2/Bcl-X Pathway in Myc-Induced Lymphomagenesis$282,000
R01 · FY2003 · CA
C-MYC FUNCTION IN APOPTOSIS, HEMATOPOIESIS AND LEUKEMIA$286,557
R01 · FY2002 · DK
REGULATION OF BCL2 BY APOPTOTIC PATHWAYS IN LEUKEMIA$219,555
R01 · FY2002 · CA
C-MYC FUNCTION IN APOPTOSIS, HEMATOPOIESIS AND LEUKEMIA$284,963
R01 · FY2001 · DK
REGULATION OF BCL2 BY APOPTOTIC PATHWAYS IN LEUKEMIA$206,950
R01 · FY2001 · CA
REGULATION OF BCL2 BY APOPTOTIC PATHWAYS IN LEUKEMIA$206,950
R01 · FY2000 · CA